U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H34O3
Molecular Weight 370.5259
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIMEXOLONE

SMILES

CCC(=O)[C@@]1(C)[C@]([H])(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])[C@]([H])(C[C@@]21C)O

InChI

InChIKey=QTTRZHGPGKRAFB-OOKHYKNYSA-N
InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/mtm/rimexolone-ophthalmic.html http://www.rxlist.com/vexol-drug.htm http://www.wikidoc.org/index.php/Rimexolone

Rimexolone is a glucocorticoid receptor agonist. Rimexolone ophthalmic (for the eyes) is used to treat eye inflammation caused by infections, injury, surgery, or other conditions. It is FDA approved for the treatment of post-operative inflammation and anterior uveitis. Common adverse reactions include hypotension, erythema, pruritus, taste sense altered, headache, blurred vision, discharge from eye, pain in eye, pharyngitis, and rhinitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VEXOL

Approved Use

VEXOL® 1% (rimexolone ophthalmic suspension) is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.

Launch Date

7.8874562E11
Primary
VEXOL

Approved Use

VEXOL® 1% (rimexolone ophthalmic suspension) is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.

Launch Date

7.8874562E11
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1091 ng × h/mL
80 mg single, intraarticular
dose: 80 mg
route of administration: Intraarticular
experiment type: SINGLE
co-administered:
RIMEXOLONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1331 ng × h/mL
120 mg single, intraarticular
dose: 120 mg
route of administration: Intraarticular
experiment type: SINGLE
co-administered:
RIMEXOLONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1786 ng × h/mL
160 mg single, intraarticular
dose: 160 mg
route of administration: Intraarticular
experiment type: SINGLE
co-administered:
RIMEXOLONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
564 ng × h/mL
40 mg single, intraarticular
dose: 40 mg
route of administration: Intraarticular
experiment type: SINGLE
co-administered:
RIMEXOLONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 % 4 times / day steady, ophthalmic
Recommended
Dose: 1 %, 4 times / day
Route: ophthalmic
Route: steady
Dose: 1 %, 4 times / day
Sources:
unhealthy
n = 197
Health Status: unhealthy
Condition: intraocular inflammation after cataract extraction
Population Size: 197
Sources:
Disc. AE: Ocular pain...
AEs leading to
discontinuation/dose reduction:
Ocular pain (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ocular pain 2%
Disc. AE
1 % 4 times / day steady, ophthalmic
Recommended
Dose: 1 %, 4 times / day
Route: ophthalmic
Route: steady
Dose: 1 %, 4 times / day
Sources:
unhealthy
n = 197
Health Status: unhealthy
Condition: intraocular inflammation after cataract extraction
Population Size: 197
Sources:
PubMed

PubMed

TitleDatePubMed
Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids.
1996 Aug
Pharmacological validation of a feline model of steroid-induced ocular hypertension.
1999 Mar
Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children.
2003 Dec
Two cases of corneal ulcer due to methicillin-resistant Staphylococcus aureus in high risk groups.
2010 Aug
Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells.
2010 Jun 15
Patents

Sample Use Guides

Post-Operative Inflammation: Apply one - two drops of Rimexolone 1% Ophthalmic Suspension into the conjunctival sac of the affected eye four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period. Anterior Uveitis: Apply one - two drops of Rimexolone 1% Ophthalmic Suspension into the conjunctival sac of the affected eye every hour during waking hours for the first week, one drop every two hours during waking hours of the second week, and then taper until uveitis is resolved.
Route of Administration: Topical
Isolated CD4+ T-cells were pre-incubated with rimexolone at different concentrations for 10 min (10(-11)/10(-8)/10(-5)M) and stimulated with anti-CD3/anti-CD28 for 96 h. Proliferation was determined by flow cytometry. The percentage of dividing cells was significantly reduced by 10(-5)M rimexolone.
Name Type Language
RIMEXOLONE
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
11.BETA.-HYDROXY-16.ALPHA.,17.ALPHA.-DIMETHYL-17-PROPIONYLANDROSTA-1,4-DIEN-3-ONE
Common Name English
RIMEXOLONE [INN]
Common Name English
RIMEXOLONE [USAN]
Common Name English
RIMEXOLON
Common Name English
RIMEXOLONE [USP MONOGRAPH]
Common Name English
RIMEXOLONE [MART.]
Common Name English
VEXOL
Brand Name English
ANDROSTA-1,4-DIEN-3-ONE, 11-HYDROXY-16,17-DIMETHYL-17-(1-OXOPROPYL)-, (11.BETA.,16,ALPHA.,17.BETA.)-
Common Name English
RIMEXOLONE [USP]
Common Name English
RIMEXOLONE [MI]
Common Name English
RIMEXOLONE [WHO-DD]
Common Name English
RIMEXOLONE [USP-RS]
Common Name English
RIMEXOLONE [ORANGE BOOK]
Common Name English
ORG-6216
Code English
RIMEXOLONE [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175450
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
WHO-VATC QS01BA13
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
WHO-ATC S01BA13
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
WHO-ATC H02AB12
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
WHO-VATC QH02AB12
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C47705
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200617
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
EVMPD
SUB10323MIG
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
USP_CATALOG
1604600
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY USP-RS
MESH
C013769
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
LACTMED
Rimexolone
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
EPA CompTox
49697-38-3
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
CAS
49697-38-3
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
DRUG CENTRAL
2384
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
MERCK INDEX
M9622
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY Merck Index
RXCUI
55681
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY RxNorm
IUPHAR
7099
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
DRUG BANK
DB00896
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
WIKIPEDIA
RIMEXOLONE
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
INN
4313
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
FDA UNII
O7M2E4264D
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY
PUBCHEM
5311412
Created by admin on Fri Jun 25 20:57:24 UTC 2021 , Edited by admin on Fri Jun 25 20:57:24 UTC 2021
PRIMARY